It has been speculated that two drugs used to treat high blood pressure and heart failure – ACE inhibitors (ACE) and angiotensin receptor blockers (ARBs) – may increase the risk of spasmodics. COVID-19.
Researchers examined the MEDLINE and EMBASE databases for detailed studies of patients treated with ACE inhibitors and / or ARB drugs. They conducted two meta-analyzes to evaluate the results of 17 trials: 1) to investigate the COVID-19 positive case rate, and 2) to determine mortality among those who entered Institute with COVID-19.
Their analyzes yielded the following findings:
- Patients on ACE inhibitors or ARBs had no increased incidence of COVID-19 infection; and
- Patients with COVID-19 hospitalized on ACE inhibitors or ARBs had no increased mortality.
A sub-analysis was also performed, focusing on studies including patients treated for hypertension. Results showed that taking ACE inhibitors and ARBs were associated with lower mortality in hospitalized COVID-19 patients with a history of hypertension.
Study lead author Yujiro Yokoyama, MD, surgeon at the Easton Hospital of St. University Medical Network. “Our results confirm that patients who have taken ACE inhibitors and ARBs should not stop taking them due to COVID-19 infection,” said Luke in Pennsylvania. “Both drugs have been shown to benefit heart and kidney disease, and this further confirms previous findings that ACE inhibitors pose no additional risk with COVID-19.”
Early in the COVID-19 epidemic, the American Heart Association issued a joint statement with the American Heart Failure Association and the American College of Cardiology to address the use of ACE inhibitors and ARB drugs in patients are at risk of developing COVID-19. Recommendations call for continued use of ACE-i or ARB drugs in patients already taking them for indications such as heart failure, hypertension or ischemic heart disease. Cardiovascular patients diagnosed with COVID-19 should be fully evaluated before adding or removing any treatment, and any changes to their treatment should be based on scientific evidence. Learn up-to-date and joint decision-making with doctors and their healthcare team.
Meta-analysis of the effect of Renin-angiotensin-aldosterone system inhibitors on Covid-19 mortality and positive assay (Exhibit 399)
Study co-authors are Hisato Takagi, MD, Ph.D; Tadao Aikawa, MD, Ph.D.; and Toshiki Kuno, MD, Ph.D. Disclosures by the authors are detailed in the summary. No external funding has been documented for this study.
Note: Part: CV19.AOS.848 – COVID-19: Risk Score and Risk Factors for Adverse Results
As the COVID-19 pandemic continues to affect people globally, research is underway to facilitate understanding of the virus in order to improve outcomes and care for patients. Cardiovascular health and drugs and the potential role each drug plays in patients with COVID-19 have been the focus of hundreds of studies. The American Heart Association will host experts presenting the latest COVID-19 research at the 2020 Scientific Sessions. The meeting will be held mostly from Friday, November 13 – Tuesday, November 17, 2020, and the premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care across the globe. world.